Pesquisar
Akebia Therapeutics Inc
AKBAAdicionar à lista de desejos
1.240USD
+0.030+2.48%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
332.19MValor de mercado
PerdaP/L TTM
Mais detalhes de Akebia Therapeutics Inc Empresa
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Informações de Akebia Therapeutics Inc
Código da empresaAKBA
Nome da EmpresaAkebia Therapeutics Inc
Data de listagemMar 20, 2014
CEOButler (John P)
Número de funcionários181
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 20
Endereço245 First Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone16178712098
Sitehttps://akebia.com/
Código da empresaAKBA
Data de listagemMar 20, 2014
CEOButler (John P)
Executivos da empresa Akebia Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+29.06%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
49.35K
-113.52%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.21M
-2.15%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
330.72K
+50.21%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
200.50K
+17.81%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
161.73K
+22.07%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
160.93K
+22.18%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
133.38K
+26.77%
Perguntas frequentes
Quem são os cinco principais acionistas de Akebia Therapeutics Inc?
Os cinco principais acionistas de Akebia Therapeutics Inc são: Mr. John P. Butler
Quantas instituições possuem ações da Akebia Therapeutics Inc (AKBA)?
Em 2026Q1, 351 instituições possuíam ações da Akebia Therapeutics Inc, com valor de mercado aproximado de 125.97M, representando 46.96% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -14935721.00.